Bio­gen sweeps out a Parkin­son’s drug on PhII fail­ure as an­a­lysts raise alarms about pro­ject­ed rev­enue slide — de­spite as­sum­ing an ad­u­canum­ab OK

Bio­gen’s high-stakes gam­ble on the Alzheimer’s drug ad­u­canum­ab just be­came some­what more des­per­ate as the big biotech pro­ject­ed a much larg­er drop in rev­enue for 2021 than had been ex­pect­ed while dump­ing a Phase II drug and tak­ing a $75 mil­lion hit.

The com­pa­ny set an awk­ward tone Wednes­day morn­ing as Bio­gen laid out a set of 2021 rev­enue that in­clud­ed “mod­est” rev­enue for ad­u­canum­ab, as­sum­ing that the FDA will go ahead and ap­prove it by its new PDU­FA date of June 7.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER